LUYE PHARMA

Luye Pharma surged 9.14% to close at HKD 2.030 on heavy volume, driven by positive Phase II top-line results for LY03015 in tardive dyskinesia (TD). The drug showed significant improvement in LSM at week 24 with a rapid onset by week 6 and a favorable safety profile. The stock opened low at HKD 1.870 and rallied steadily to hit intraday high of HKD 2.030 in the afternoon session, with turnover exceeding HKD 200 million. Financially, net profit surged over 200% YoY in Q3-Q4, while EPS improved to HKD 0.0422, though revenue growth remained single-digit. The price reclaimed the 20-day MA (HKD 1.877), yet YTD declines of 26.71% and a 54.79% gap from the 52-week high of HKD 4.49 persist, with a PB of 0.47x. However, the 60-day MA (HKD 2.328) still looms as overhead resistance.